We are live on ! Find out more
REPL icon

Replimune Group

150 hedge funds and large institutions have $548M invested in Replimune Group in 2024 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 58 increasing their positions, 36 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

61% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 36

53% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 19

7% more funds holding

Funds holding: 140150 (+10)

8% less capital invested

Capital invested by funds: $594M → $548M (-$46.5M)

10.13% less ownership

Funds ownership: 119.34%109.21% (-10%)

33% less funds holding in top 10

Funds holding in top 10: 32 (-1)

38% less call options, than puts

Call options by funds: $837K | Put options by funds: $1.35M

Holders
150
Holders Change
+10
Holders Change %
+7.14%
% of All Funds
2.16%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.03%
New
29
Increased
58
Reduced
36
Closed
19
Calls
$837K
Puts
$1.35M
Net Calls
-$516K
Net Calls Change
+$1.45M
Name Holding Trade Value Shares
Change
Change in
Stake
BBA
1
Baker Bros. Advisors
New York
$78M
T. Rowe Price Associates
2
T. Rowe Price Associates
Maryland
$53.5M +$5.74M +699,679 +12%
State Street
3
State Street
Massachusetts
$53M +$11.3M +1,375,175 +27%
FIS
4
FCPM III Services
Netherlands
$39.8M -$410 -50 -0%
BlackRock
5
BlackRock
New York
$37.7M +$607K +74,071 +2%
RG
6
Redmile Group
California
$30.5M -$1.11M -135,275 -3%
OFM
7
Omega Fund Management
Massachusetts
$24.5M
Vanguard Group
8
Vanguard Group
Pennsylvania
$22.6M +$267K +32,555 +1%
CCM
9
Camber Capital Management
Massachusetts
$22.5M +$14.4M +1,750,000 +175%
Morgan Stanley
10
Morgan Stanley
New York
$21.7M -$51.2M -6,240,422 -70%
AVLSA
11
Atlas Venture Life Science Advisors
Massachusetts
$17.1M
Geode Capital Management
12
Geode Capital Management
Massachusetts
$9.74M +$383K +46,681 +4%
JFG
13
Jefferies Financial Group
New York
$8.17M +$8.2M +1,000,000 New
D.E. Shaw & Co
14
D.E. Shaw & Co
New York
$8.15M +$6.19M +754,780 +311%
Dimensional Fund Advisors
15
Dimensional Fund Advisors
Texas
$7.99M -$2.83M -345,117 -26%
DM
16
Deerfield Management
New York
$6.56M -$8.27M -1,008,726 -56%
GTC
17
Ghost Tree Capital
New York
$5.31M +$2.05M +250,000 +63%
Rafferty Asset Management
18
Rafferty Asset Management
New York
$5.25M +$1.47M +178,681 +39%
Citigroup
19
Citigroup
New York
$4.43M +$2.95M +359,228 +196%
Deutsche Bank
20
Deutsche Bank
Germany
$4.27M +$3.15M +384,267 +279%
Goldman Sachs
21
Goldman Sachs
New York
$4.19M -$14.2M -1,725,543 -77%
EA
22
Emerald Advisers
Pennsylvania
$4.02M -$382K -46,622 -9%
Northern Trust
23
Northern Trust
Illinois
$3.95M +$14.8K +1,810 +0.4%
Millennium Management
24
Millennium Management
New York
$3.77M +$3.66M +446,836 +2,974%
Norges Bank
25
Norges Bank
Norway
$3.76M +$3.77M +459,900 New

REPL Hedge Fund Activity: Q1 2024 in Review

150 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Replimune Group (REPL) for Q1 2024, worth a combined $548M — down 7.8% from $594M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new REPL positions and 19 closed out — a net gain of 10 holders — while 58 added to existing stakes and 36 trimmed.

The largest buyer was Camber Capital Management, adding an estimated $14.4M. The largest seller was Morgan Stanley, cutting an estimated $51.2M.

  • 150 institutional investors held Replimune Group (REPL) as of Q1 2024, up from 140 in Q4 2023.
  • Funds reported $548M of Replimune Group stock for Q1 2024, down 7.8% quarter-over-quarter.
  • 29 funds opened new Replimune Group positions in Q1 2024 and 19 closed out, a net change of +10 holders.
  • The largest Replimune Group buyer in Q1 2024 was Camber Capital Management, an estimated $14.4M added.
  • The largest Replimune Group seller in Q1 2024 was Morgan Stanley, an estimated $51.2M sold.

Based on aggregated 13F filings for Q1 2024.